Search results
23 lis 2020 · In this article, we will review the signalment, clinical signs, histopathology and treatment outcome of pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus in dogs, cats and horses; where pertinent, we compare the animal diseases to their human homologue.
24 sie 2020 · The following first-line therapies of moderate and severe pemphigus are recommended: Rituximab (two infusions of 1 g two weeks apart) associated with systemic corticosteroids (prednisone 1 mg/kg/day) with a progressive tapering in order to stop corticosteroids after 6 months (4.9 ± 0.4). 18, 31, 32.
15 paź 2024 · Pemphigus vulgaris is a rare autoimmune blistering disease, which manifests due to antibodies binding to molecules in the skin, specifically desmoglein 1 and desmoglein 3. The worldwide incidence is 0.1–0.5 per 100,000 and appears to be more common in India, China, Malaysia, and the Middle East.
23 lis 2020 · In this article, we will review the signalment, clinical signs, histopathology and treatment outcome of pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus in dogs, cats and horses; where pertinent, we compare the animal diseases to their human homologue.
25 lis 2023 · All adult patients who had confirmed diagnosis of pemphigus vulgaris or pemphigus foliaceus, experienced treatment with rituximab (RTX) and were finally subjected to a combination therapy with mycophenolate mofetil, dapsone, or methotrexate due to:
Newer-generation anti-CD20 antibodies like rituximab are a safer alternative for treating patients with pemphigus vulgaris. This review introduces possibly safer alternatives to rituximab. This information can guide clinicians and researchers to developing and using these alternatives.
28 lis 2019 · There is evidence that the anti‐CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add?
